CASi Platform Switch Therapeutics offers the CASi (Conditionally Activated siRNA) platform that enables cell-selective RNA interference, presenting a licensing or co-development opportunity for pharma and biotech partners seeking precise genetic medicines for CNS and systemic indications.

CNS and Systemic The company targets CNS and systemic indications with significant unmet needs, providing a clear focus for business development discussions with neuroscience and rare-disease programs that could benefit from targeted gene knockdown technologies.

Leadership and Partnerships Recent leadership additions, including a Chief Technology Officer appointment in 2024 and a board member with prior pharma/biotech oversight, signal readiness for formal collaborations, sponsored research, and licensing discussions.

Funding Momentum A $52M Series A in 2023 alongside modest revenue suggests strong investor backing and runway to pursue early collaborative programs, making it a suitable partner for funded preclinical studies.

Strategic Location Based in the San Francisco Bay Area, Switch Therapeutics benefits from proximity to a dense biotech ecosystem and potential access to regional CROs, academic collaborators, and early-stage pharma outreach.